Added to YB: 2025-12-04
Pitch date: 2025-12-01
MDNA.TO [bullish]
Medicenna Therapeutics Corp.
-32.1%
current return
Author Info
Penny Queen focuses on undiscovered value, deep dives, swing trades and special situations. Sign up for the newsletter.
Company Info
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.
Market Cap
CAD 133.5M
Pitch Price
CAD 1.62
Price Target
20.00 (+1718%)
Dividend
N/A
EV/EBITDA
-5.42
P/E
-9.33
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Major Catalyst and the 150x Valuation Gap in IL-2 Immunotherapy - Medicenna Therapeutics Corp.
MDNA.TO: Lymph node-targeting IL-2 showing 40% ORR in checkpoint-resistant patients vs 5% standard care; 3 end-stage patients in durable remission 80+ weeks; 4 accelerated approval shots on Dec 10 data readout; $75M vs Takeda's $11B+ comparable; runs to mid-2026.
Read full article (8 min)